Literature DB >> 36136155

Epidemiology, severity, and risk of SARS-CoV-2-related relapse in children and young adults affected by idiopathic nephrotic syndrome: a retrospective observational cohort study.

William Morello1, Federica Alessandra Vianello2, Chiara Bulgaro2, Giovanni Montini2,3.   

Abstract

BACKGROUND: Children with underlying kidney diseases display a mild course of SARS-CoV-2 infection, but they only accounted for a minority of cases until the spread of the Omicron variant. Nonetheless, idiopathic nephrotic syndrome (INS) has been advocated as a predictor of worse outcome.
METHODS: We investigated the spread, severity, and risk of relapse related to SARS-CoV-2 infection among children with INS. The incidence and characteristics of SARS-CoV-2 infections, immunosuppression, and vaccination status were retrospectively collected from the beginning of the pandemic to May 31, 2022.
RESULTS: We enrolled 176 patients (73 females, median age 10.22 years); 28 had a steroid-resistant disease, and 108 (61.4%) were on immunosuppressive therapy. Sixty-one (34.7%) patients reported a SARS-CoV-2 infection, with incidence peaking between December 2021 and January 2022. No hospitalization or deaths were reported, and symptoms were absent or mild. The rate of SARS-CoV-2 infection was similar in children with and without immunosuppression (33.8% vs 35.2%; p = 0.85). None of the 38 immunosuppressed patients discontinued the therapy, but they had a longer time to negativization (13.31 vs. 10.04 days; p = 0.03). Proteinuria was detected in 7 patients, but only one had a relapse requiring steroid therapy, with prompt remission and a mild course.
CONCLUSIONS: After the spread of the Omicron variant, the rate of SARS-CoV-2 infection in children with INS was much higher than previously reported. In this large cohort, symptoms were mild, even in immunosuppressed patients and those with proteinuria. During the infection, transient proteinuria was common with a low rate of relapses. A higher resolution version of the Graphical abstract is available as Supplementary information.
© 2022. The Author(s), under exclusive licence to International Pediatric Nephrology Association.

Entities:  

Keywords:  COVID-19; Children; Idiopathic nephrotic syndrome; Proteinuria; Relapse; SARS-CoV-2; Vaccines

Year:  2022        PMID: 36136155     DOI: 10.1007/s00467-022-05736-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.651


  16 in total

Review 1.  Idiopathic nephrotic syndrome in children.

Authors:  Damien G Noone; Kazumoto Iijima; Rulan Parekh
Journal:  Lancet       Date:  2018-06-14       Impact factor: 79.321

2.  Incidence Rates, Household Infection Risk, and Clinical Characteristics of SARS-CoV-2 Infection Among Children and Adults in Utah and New York City, New York.

Authors:  Fatimah S Dawood; Christina A Porucznik; Vic Veguilla; Joseph B Stanford; Jazmin Duque; Melissa A Rolfes; Ashton Dixon; Priyam Thind; Emily Hacker; Maria Julia E Castro; Zuha Jeddy; Michael Daugherty; Kim Altunkaynak; Danielle Rentz Hunt; Utsav Kattel; Jennifer Meece; Melissa S Stockwell
Journal:  JAMA Pediatr       Date:  2022-01-01       Impact factor: 26.796

3.  Incidence Rates and Clinical Outcomes of SARS-CoV-2 Infection With the Omicron and Delta Variants in Children Younger Than 5 Years in the US.

Authors:  Lindsey Wang; Nathan A Berger; David C Kaelber; Pamela B Davis; Nora D Volkow; Rong Xu
Journal:  JAMA Pediatr       Date:  2022-08-01       Impact factor: 26.796

4.  SARS-CoV-2 infection in children with chronic kidney disease.

Authors:  Sudarsan Krishnasamy; Mukta Mantan; Kirtisudha Mishra; Kanika Kapoor; Megha Brijwal; Manish Kumar; Shobha Sharma; Swarnim Swarnim; Rajni Gaind; Priyanka Khandelwal; Pankaj Hari; Aditi Sinha; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2021-09-14       Impact factor: 3.651

5.  Impact of COVID-19 Pandemic in Children with CKD or Immunosuppression.

Authors:  Antonio Mastrangelo; William Morello; Enrico Vidal; Isabella Guzzo; Luigi Annicchiarico Petruzzelli; Elisa Benetti; Marco Materassi; Mario Giordano; Andrea Pasini; Ciro Corrado; Giuseppe Puccio; Roberto Chimenz; Carmine Pecoraro; Laura Massella; Licia Peruzzi; Giovanni Montini
Journal:  Clin J Am Soc Nephrol       Date:  2020-12-14       Impact factor: 8.237

6.  Prevalence of SARS-CoV-2-IgG Antibodies in Children with CKD or Immunosuppression.

Authors:  William Morello; Antonio Mastrangelo; Isabella Guzzo; Lisa Cusinato; Luigi Annicchiarico Petruzzelli; Chiara Benevenuta; Laura Martelli; Roberto Dall'Amico; Federica Alessandra Vianello; Giuseppe Puccio; Laura Massella; Elisa Benetti; Carmine Pecoraro; Licia Peruzzi; Giovanni Montini
Journal:  Clin J Am Soc Nephrol       Date:  2021-06-07       Impact factor: 10.614

Review 7.  The Italian Society for Pediatric Nephrology (SINePe) consensus document on the management of nephrotic syndrome in children: Part I - Diagnosis and treatment of the first episode and the first relapse.

Authors:  Andrea Pasini; Elisa Benetti; Giovanni Conti; Luciana Ghio; Marta Lepore; Laura Massella; Daniela Molino; Licia Peruzzi; Francesco Emma; Carmelo Fede; Antonella Trivelli; Silvio Maringhini; Marco Materassi; Giovanni Messina; Giovanni Montini; Luisa Murer; Carmine Pecoraro; Marco Pennesi
Journal:  Ital J Pediatr       Date:  2017-04-21       Impact factor: 2.638

8.  COVID-19 in children and young adults with kidney disease: risk factors, clinical features and serological response.

Authors:  Jenny Weinbrand-Goichberg; Efrat Ben Shalom; Choni Rinat; Sapir Choshen; Shimrit Tzvi-Behr; Yaacov Frishberg; Rachel Becker-Cohen
Journal:  J Nephrol       Date:  2021-10-15       Impact factor: 4.393

9.  The severity of COVID-19 in children on immunosuppressive medication.

Authors:  Matko Marlais; Tanja Wlodkowski; Marina Vivarelli; Lars Pape; Burkhard Tönshoff; Franz Schaefer; Kjell Tullus
Journal:  Lancet Child Adolesc Health       Date:  2020-05-13

10.  Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.

Authors:  Salim S Abdool Karim; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2021-12-03       Impact factor: 202.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.